Clinical Trial Detail

NCT ID NCT03675737
Title Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Participants Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-859/KEYNOTE-859)
Recruitment Recruiting
Gender both
Phase Phase III
Variant Requirements Yes
Sponsors Merck Sharp & Dohme Corp.
Indications

gastroesophageal junction adenocarcinoma

gastric adenocarcinoma

Therapies

Capecitabine + Oxaliplatin

Capecitabine + Oxaliplatin + Pembrolizumab

Cisplatin + Fluorouracil + Pembrolizumab

Cisplatin + Fluorouracil

Age Groups: adult senior

Additional content available in CKB BOOST